N. Kallewaard

发表

Cooperativity of actin and microtubule elements during replication of respiratory syncytial virus.

J. Crowe, N. Kallewaard, Amber L Bowen, 2005, Virology.

Potently neutralizing and protective human antibodies against SARS-CoV-2

Lisa E. Gralinski, Larissa B. Thackray, Benjamin K. Mueller, 2020, Nature.

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

J. Dye, J. Mascola, J. M. Sauder, 2022, Cell Reports.

VH1–46 Is the Dominant Immunoglobulin Heavy Chain Gene Segment in Rotavirus-Specific Memory B Cells Expressing the Intestinal Homing Receptor α4β71

B. LaFleur, J. Crowe, H. Greenberg, 2005, The Journal of Immunology.

Automated image analysis of atomic force microscopy images of rotavirus particles.

M J Doktycz, J. Morrell-Falvey, M. Doktycz, 2006, Ultramicroscopy.

Generation of recombinant human monoclonal antibodies to rotavirus from single antigen-specific B cells selected with fluorescent virus-like particles.

J. Crowe, H. Greenberg, K. Kusuhara, 2003, Journal of immunological methods.

Infant and Adult Human B Cell Responses to Rotavirus Share Common Immunodominant Variable Gene Repertoires 1

B. LaFleur, J. Crowe, John V. Williams, 2003, The Journal of Immunology.

DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections

N. Sardesai, D. Weiner, Jian Yan, 2017, npj Vaccines.

Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza

N. Kallewaard, F. Dubovsky, R. Mallory, 2018, Antimicrobial Agents and Chemotherapy.

Survival during influenza-associated bacterial superinfection improves following viral- and bacterial-specific monoclonal antibody treatment.

K. M. Robinson, J. Alcorn, N. Kallewaard, 2019, JCI insight.

The Hemagglutinin A Stem Antibody MEDI8852 Prevents and Controls Disease and Limits Transmission of Pandemic Influenza Viruses

Catharine I Paules, K. Subbarao, S. Lakdawala, 2017, The Journal of infectious diseases.

A novel antibody discovery platform identifies anti-influenza A broadly neutralizing antibodies from human memory B cells

Herren Wu, Qing Zhu, Xiaodong Xiao, 2016, mAbs.

Tissue-specific deletion of the coxsackievirus and adenovirus receptor protects mice from virus-induced pancreatitis and myocarditis.

J. Bergelson, Melissa D. Sánchez, N. Kallewaard, 2009, Cell host & microbe.

The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination

R. Higgs, Myron S. Cohen, N. Kallewaard, 2022, Science Translational Medicine.

Antibody Response to Rotavirus Functional Maturation of the Human

B. McKinney, J. Crowe, B. Prasad, 2008 .

Variable Gene Repertoires Rotavirus Share Common Immunodominant Infant and Adult Human B Cell Responses to

J. Crowe, H. Greenberg, K. Kusuhara, 2003 .

The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans

J. Dye, M. Pangalos, A. Herbert, 2022, Science Translational Medicine.

AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans

J. Dye, M. Pangalos, A. Herbert, 2021, medRxiv.

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals

Lisa E. Gralinski, Larissa B. Thackray, Samuel B. Day, 2020, bioRxiv.

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

D. Skovronsky, R. Higgs, T. Holzer, 2021, The New England journal of medicine.

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

J. Dye, J. Mascola, J. M. Sauder, 2021, bioRxiv.

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.

D. Skovronsky, R. Higgs, T. Holzer, 2021, JAMA.

Respiratory Syncytial Virus and Human Metapneumovirus Infections in Three-Dimensional Human Airway Tissues Expose an Interesting Dichotomy in Viral Replication, Spread, and Inhibition by Neutralizing Antibodies

C. Moncman, R. Dutch, N. Kallewaard, 2020, Journal of Virology.

Prevalence and Significance of Substitutions in the Fusion Protein of Respiratory Syncytial Virus Resulting in Neutralization Escape From Antibody MEDI8897

P. McTamney, Qing Zhu, J. Suzich, 2018, The Journal of infectious diseases.

Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes

P. Collins, J. Skehel, F. Sallusto, 2016, Cell.

Tackling influenza with broadly neutralizing antibodies

A. Lanzavecchia, Qing Zhu, E. Cameroni, 2017, Current Opinion in Virology.

Rapid development of broadly influenza neutralizing antibodies through redundant mutations

Qing Zhu, Mathilde Foglierini, Leontios Pappas, 2014, Nature.

A Broadly Neutralizing Human Monoclonal Antibody Directed against a Novel Conserved Epitope on the Influenza Virus H3 Hemagglutinin Globular Head

Qing Zhu, J. McAuliffe, F. Palmer-Hill, 2014, Journal of Virology.

DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections

N. Sardesai, D. Weiner, Jian Yan, 2017, npj Vaccines.

A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants

N. Patel, Qing Zhu, J. McAuliffe, 2017, Science Translational Medicine.

Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19

D. Skovronsky, M. Frieman, N. Kallewaard, 2022, medRxiv.

Using the natural evolution of a rotavirus-specific human monoclonal antibody to predict the complex topography of a viral antigenic site

Jens Meiler, James E Crowe, Brett A McKinney, 2007, Immunome research.

The effect of anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, on endogenous immune response to COVID-19 vaccination

R. Higgs, N. Kallewaard, M. Cohen, 2021, medRxiv.

Functional Maturation of the Human Antibody Response to Rotavirus1

Brett A. McKinney, James E. Crowe, B. McKinney, 2008, The Journal of Immunology.

Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together

R. Higgs, N. Kallewaard, P. Vaillancourt, 2021, Frontiers in Immunology.

Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies

Weichen Xu, Y. Loo, N. Kallewaard, 2022, mAbs.

Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab

T. Doman, R. Higgs, T. Holzer, 2022, Journal of translational medicine.

Genetic and structural determinants of virus neutralizing antibodies

Frances S. House, J. Crowe, N. Kallewaard, 2001, Immunologic research.

Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes

P. Collins, J. Skehel, F. Sallusto, 2016, Cell.

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

J. Dye, J. Mascola, J. M. Sauder, 2022, Cell Reports.